Open Access

Detection of „Hotspot Mutations in Catalytic Subunit of Phosphatidylinositol 3-Kinase (Pik3ca) by Allele-Specific Polymerase Chain Reaction


Cite

1. Wu G, Xing M, Mambo E.et al. Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res 2005; 7(5):609-16.10.1186/bcr1262124212816168105Search in Google Scholar

2. Karakas B, Bachman KE, Park BH. Mutation of the PIK3CA oncogene in human cancers. Br J Cancer 2006; 94:455-9.10.1038/sj.bjc.6602970236117316449998Search in Google Scholar

3. Di Cosimo S, Baselga J. Phosphoinositide 3-kinase mutations in breast cancer: a „good“ activating mutation? Clin Cancer Res 2009; 15(16):5017-9.Search in Google Scholar

4. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296:1655-7.10.1126/science.296.5573.165512040186Search in Google Scholar

5. Samuels Y, Ericson K. Oncogenic PI3K and its role in cancer. Curr Opin Oncol 2006; 18:77-82.10.1097/01.cco.0000198021.99347.b916357568Search in Google Scholar

6. Barbareschi M, Buttitta F, Felicioni L et al. Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res 2007; 13:6064-9.10.1158/1078-0432.CCR-07-026617947469Search in Google Scholar

7. Little S. Amplification-refractory mutation system (ARMS) analysis of point mutations. Curr Protoc Hum Genet 2001; 7:9.8.1-9.8.12.Search in Google Scholar

8. Darawi MN, Ai-Vyrn C, Ramasamy K et al. Allele-specific polymerase chain reaction for detection of Alzheimer s disease-related single nucleotide polymorphisms. BMC Med Genet 2013, 14:27.10.1186/1471-2350-14-27363588823419238Search in Google Scholar

9. Whitman KD, Kaplan DR, Schaffhausen B et al. Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation. Nature 1985; 11(6016):239-42.10.1038/315239a02987699Search in Google Scholar

10. Janku F, Tsimberidou AM, Garrido-Laguna I et al. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther 2011; 10(3):558-65.10.1158/1535-7163.MCT-10-0994307216821216929Search in Google Scholar

11. Dumont AG, Dumont SN, Trent JC. The favourable impact of PIK3CA mutations on survival: an analysis of 2587 patients with breast cancer. Chin J Cancer 2012; 31(7):327-34.10.5732/cjc.012.10032377749722640628Search in Google Scholar

12. Miled N, Yan Y, Hon WC et al. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science 2007; 317(5835):239-42.10.1126/science.113539417626883Search in Google Scholar

13. Zhao L, Vogt PK. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci USA 2008; 105(7):2652-7.10.1073/pnas.0712169105226819118268322Search in Google Scholar

14. German S, Aslam HM, Saleem S, Raees A et al. Carcinogenesis of PIK3CA. Hered Cancer Clin Pract 2013; 11(1):5.10.1186/1897-4287-11-5370245623768168Search in Google Scholar

eISSN:
1335-8421
Language:
English
Publication timeframe:
3 times per year
Journal Subjects:
Medicine, Clinical Medicine, Internal Medicine, Cardiology